This review addresses this gap by evaluating MSC therapy across preclinical and clinical studies involving various causes of CKD, focusing on key inflammatory and fibrotic mediators—including IL-6, TNF-α, and TGF-β—as well as functional markers like creatinine, BUN, GFR, and urinary protein indices. This evidence concerns the gene IL6 and chronic kidney disease.